Allergenic Effect of Ambrosia in Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Rambam Health Care Campus.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01413256
First received: August 9, 2011
Last updated: NA
Last verified: August 2011
History: No changes posted
  Purpose

Background:

Respiratory allergic reaction causes great suffering to millions of people worldwide. One of the most known allergen- is the pollen from vegetation, ragweed. Genus Ambrosia Ambrosia belonged to the complex ragweed flowers are pollinated by the wind and the plant's male flowers produce large quantities of small grains of pollen and airborne over long distances and those causes allergic reactions. The plant blooms between June and October, creating a second wave after wave of allergy caused by spring blossoms.

This plant originated in North America has invaded many areas in Europe and in recent years, taking over large areas in Israel, Hula Valley and northern Acre Emek Hefer for a pen and layers to the south. After ragweed plants are based in particular they spread quickly and invade agricultural fields and significantly reduce the crop.

High allergenic ragweed is a health hazard to humans. Ragweed plant investigated many aspects of North America and Europe in recent decades and extensive literature on ambrosia, but this is the first time ragweed study focuses on Israel.

Working hypothesis and aims:

Goal of this study is to identify the existence and nature of the sensitivity distribution of ragweed in Israel.

Importance of research:

A. Ragweed allergen testing and comparing the effect of exposure to plants on the sensitivity of the allergic Israeli patients

B. The inclusion of ragweed allergen in the diagnostic and therapeutic panel


Condition
Allergy
Ambrosia
Ragweed

Study Type: Observational
Study Design: Observational Model: Cohort

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 200
Study Start Date: October 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

respiratory allergic patients

Criteria

Inclusion Criteria:

  • respiratory allergic patients

Exclusion Criteria:

  • non respiratory allergic patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01413256

Contacts
Contact: Eduardo Shahar, PI +972502061699 ed_shahar@rambam.health.gov.il

Sponsors and Collaborators
Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: EDUARDO SHAHAR, RAMBAM MEDICAL CENTER
ClinicalTrials.gov Identifier: NCT01413256     History of Changes
Other Study ID Numbers: 0015-11-RMB
Study First Received: August 9, 2011
Last Updated: August 9, 2011
Health Authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research

ClinicalTrials.gov processed this record on August 18, 2014